Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Share-based Compensation (2019 - 2025)

Revolution Medicines has reported Share-based Compensation over the past 7 years, most recently at $33.7 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $33.7 million for Q4 2025, up 50.17% from a year ago — trailing twelve months through Dec 2025 was $118.4 million (up 49.49% YoY), and the annual figure for FY2025 was $118.4 million, up 49.49%.
  • Share-based Compensation for Q4 2025 was $33.7 million at Revolution Medicines, up from $30.8 million in the prior quarter.
  • Over the last five years, Share-based Compensation for RVMD hit a ceiling of $33.7 million in Q4 2025 and a floor of $3.4 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $13.3 million (2023), compared with a mean of $15.6 million.
  • Biggest five-year swings in Share-based Compensation: soared 205.76% in 2023 and later fell 11.75% in 2024.
  • Revolution Medicines' Share-based Compensation stood at $6.2 million in 2021, then skyrocketed by 34.19% to $8.3 million in 2022, then soared by 205.76% to $25.4 million in 2023, then dropped by 11.75% to $22.4 million in 2024, then skyrocketed by 50.17% to $33.7 million in 2025.
  • The last three reported values for Share-based Compensation were $33.7 million (Q4 2025), $30.8 million (Q3 2025), and $28.8 million (Q2 2025) per Business Quant data.